Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

607 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute hypertriglyceridemia in patients with COVID-19 receiving tocilizumab.
Morrison AR, Johnson JM, Ramesh M, Bradley P, Jennings J, Smith ZR. Morrison AR, et al. Among authors: ramesh m. J Med Virol. 2020 Oct;92(10):1791-1792. doi: 10.1002/jmv.25907. Epub 2020 Jun 3. J Med Virol. 2020. PMID: 32314799 Free PMC article. No abstract available.
Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19.
Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, Miller J, Kenney RM, Alangaden G, Ramesh MS; Henry Ford COVID-19 Management Task Force. Fadel R, et al. Among authors: ramesh ms. Clin Infect Dis. 2020 Nov 19;71(16):2114-2120. doi: 10.1093/cid/ciaa601. Clin Infect Dis. 2020. PMID: 32427279 Free PMC article.
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19.
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M; Henry Ford COVID-19 Task Force. Arshad S, et al. Among authors: ramesh ms. Int J Infect Dis. 2020 Aug;97:396-403. doi: 10.1016/j.ijid.2020.06.099. Epub 2020 Jul 2. Int J Infect Dis. 2020. PMID: 32623082 Free PMC article.
A sound approach: Hydroxychloroquine reduces mortality in severe COVID-19.
Zervos M, Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W. Zervos M, et al. Among authors: ramesh ms. Int J Infect Dis. 2020 Oct;99:138-139. doi: 10.1016/j.ijid.2020.07.059. Epub 2020 Jul 31. Int J Infect Dis. 2020. PMID: 32745629 Free PMC article. No abstract available.
Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.
ACTIV-3/TICO Bamlanivimab Study Group; Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnower BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Goodman AL, Chang W, Dewar RL, Gerry NP, Higgs ES, Highbarger H, Murray DD, Murray TA, Natarajan V, Paredes R, Parmar MKB, Phillips AN, Reilly C, Rupert AW, Sharma S, Shaw-Saliba K, Sherman BT, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Davey VJ, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. ACTIV-3/TICO Bamlanivimab Study Group, et al. Ann Intern Med. 2022 Feb;175(2):234-243. doi: 10.7326/M21-3507. Epub 2021 Dec 21. Ann Intern Med. 2022. PMID: 34928698 Free PMC article. Clinical Trial.
607 results